NanoViricides (NYSE:NNVC) Trading Down 5.6% – Time to Sell?

Shares of NanoViricides, Inc. (NYSE:NNVC) traded down 5.6% during mid-day trading on Thursday . The company traded as low as $0.85 and last traded at $0.85. 252,830 shares were traded during mid-day trading, a decline of 15% from the average session volume of 297,530 shares. The stock had previously closed at $0.90.

Analyst Ratings Changes

Separately, Alliance Global Partners began coverage on NanoViricides in a research report on Tuesday, December 16th. They set a “buy” rating for the company. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, NanoViricides presently has a consensus rating of “Buy”.

NanoViricides Price Performance

The stock has a 50 day moving average of $1.16 and a 200 day moving average of $1.38. The firm has a market cap of $18.98 million, a P/E ratio of -1.22 and a beta of 1.32.

Institutional Trading of NanoViricides

An institutional investor recently raised its position in NanoViricides stock. Susquehanna International Group LLP raised its holdings in shares of NanoViricides, Inc. (NYSE:NNVC) by 37.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 52,217 shares of the company’s stock after acquiring an additional 14,217 shares during the period. Susquehanna International Group LLP owned about 0.29% of NanoViricides worth $75,000 at the end of the most recent reporting period. 10.30% of the stock is owned by hedge funds and other institutional investors.

NanoViricides Company Profile

NanoViricides, Inc is a clinical-stage biotechnology company focused on the development of novel antiviral therapies using its proprietary nanomicelle technology. The company designs polymeric, virus-targeted nanoviricides that seek to neutralize viral pathogens by binding to specific viral surface proteins and destroying their structural integrity. NanoViricides’ platform is intended to offer broad-spectrum activity against a range of enveloped viruses, positioning it as a potential solution for both existing and emerging viral threats.

The company’s pipeline includes preclinical and early clinical candidates targeting seasonal and pandemic influenza strains, as well as investigational programs for coronaviruses, hepatitis, dengue, HIV and other viruses.